|
US2020338072A1
|
|
Method of treating coccidioides infection
|
|
GB201719873D0
|
|
Pharmaceutical formulation
|
|
GB201609222D0
|
|
Pharmaceutical formulation
|
|
CN107207470A
|
|
Antifungal agent
|
|
GB201512286D0
|
|
Chemical compounds
|
|
GB201505891D0
|
|
Antifungal agents
|
|
GB201420743D0
|
|
Antifungal agents
|
|
GB0909743D0
|
|
Antifungal targgt
|
|
EP2283006A1
|
|
Pyrrole antifungal agents
|
|
GB0819696D0
|
|
Antifungal combination therapy
|
|
GB0809773D0
|
|
Antifungal combination therapy
|
|
GB0809359D0
|
|
Antifungul target
|
|
GB0808029D0
|
|
Antifungal target
|
|
GB0807532D0
|
|
Antifungal agents
|
|
GB0710121D0
|
|
Antifungal agents
|
|
GB0707519D0
|
|
Fungal genes of novel function
|
|
GB0623209D0
|
|
Antifungal agents
|
|
NZ563397A
|
|
Antifungal agents comprising indolizinyl derivatives
|
|
GB0607841D0
|
|
Antifungal agents
|
|
GB0607097D0
|
|
Fungal genes of novel function
|
